31 January 2022 : Meta-Analysis
Utility of Pretreatment Blood Platelet-To-Lymphocyte Ratio in Prediction of Clinical Outcomes and Chemosensitivity in Patients with Advanced Gastric Cancer: A Meta-Analysis
Xiulan Peng1AE*, Wei Zeng2BF, Bing Tang3CF, Anbing He1B, Min Zhang1B, Renfeng Luo4ABDOI: 10.12659/MSM.933449
Med Sci Monit 2022; 28:e933449
Table 1 Baseline characteristics of eligible studies for this meta-analysis.
| Author | Year | Country | study design | Period | Patients n | Age (y) median (range) | Sex (M/F) |
|---|---|---|---|---|---|---|---|
| Aliustaoglu | 2010 | Turkey | Retrospective | 2004–2008 | 168 | 60.1 (28–83) | 114/54 |
| Lee | 2013 | Korea | Retrospective | 2007–2010 | 174 | 55 (24–74) | 110/64 |
| Wang | 2015 | China | Retrospective | 2010–2011 | 120 | 68 (32–82) | 75/45 |
| Aidemir | 2015 | Turkey | Retrospective | 2006–2013 | 50 | 65 (40–82) | 30/20 |
| Gong | 2017 | China | Retrospective | 2007–2015 | 91 | 55 (26–70) | 69/22 |
| Mimatsu | 2017 | Japan | Retrospective | 2006–2016 | 33 | NA | 27/6 |
| Tang | 2018 | China | Retrospective | 2010–2016 | 104 | 65 (31–78) | 74/30 |
| Petrillo | 2019 | Italy | Retrospective | 2010–2017 | 151 | 62 (26–85) | 97/54 |
| Wang | 2018 | China | Retrospective | 2005–2013 | 273 | 57 | 186/87 |
| Zhou | 2020 | China | Retrospective | 2010–2018 | 537 | 55 (25–83) | 321/216 |
| Zhao | 2020 | China | Retrospective | 2012–2016 | 110 | NA | 84/26 |
| Ohe | 2020 | Japan | Retrospective | 2005–2018 | 41 | 65 (30–78) | 34/7 |
| Toyokawa | 2020 | Japan | Retrospective | 1997–2012 | 225 | 68 | 114/111 |
| Huang | 2020 | China | Retrospective | 2008–2017 | 304 | NA | 198/106 |
| Wang | 2020 | China | Retrospective | 2010–2017 | 466 | 60 (20–88) | 327/139 |
| Gu | 2020 | China | Prospective | 2013–2016 | 346 | NA | NA |
| Zhai | 2021 | China | Retrospective | 2007–2014 | 306 | 58 (28–85) | 245/61 |
| Aliustaoglu | 160 | NA | Chemotherapy | NA | OS | 6 | |
| Lee | 160 | NA | Chemotherapy | 14.9 (1–47.9) | OS, PFS | 7 | |
| Wang | 235 | Median | Chemotherapy | 40 | OS | 6 | |
| Aidemir | 170 | Median | Chemotherapy | NA | OS | 7 | |
| Gong | 161 | ROC curve | Mixed | 22 (8–67) | OS | 8 | |
| Mimatsu | 200 | NA | Mixed | NA | OS | 7 | |
| Tang | 130.7 | ROC curve | Mixed | NA | OS | 7 | |
| Petrillo | 157 | Median | Chemotherapy | 29 (20.4–37.5) | OS | 8 | |
| Wang | 210.6 | ROC curve | Chemotherapy | NA | OS | 7 | |
| Zhou | 284 | ROC curve | Chemotherapy | NA | OS, PFS | 8 | |
| Zhao | 143.39 | ROC curve | chemotherapy | 11.6 | OS | 8 | |
| Ohe | 180 | ROC curve | chemotherapy | NA | OS | 7 | |
| Toyokawa | 172 | ROC curve | Mixed | 80 (69–124) | OS | 9 | |
| Huang | 107.7 | X-tile | Mixed | 28.01 (1–99) | OS | 8 | |
| Wang | 174.79 | Median | Chemotherapy | NA | OS, PFS | 8 | |
| Gu | 154 | ROC curve | Mixed | 50 (4–83) | DFS | 7 | |
| Zhai | 128 | ROC curve | Mixed | 11 | OS | 9 | |
| NA – not available; OS – overall survival; DFS – disease-free survival; NOS – Newcastle-Ottawa scale; ROC – receiver operating characteristics curve; PLR – platelet-to-lymphocyte ratio. | |||||||